CSL Limited (OTCMKTS:CSLLY) has been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company.
Several equities research analysts have recently weighed in on the company. Credit Suisse Group upgraded CSL from a “neutral” rating to an “outperform” rating in a research report on Tuesday, March 23rd. Zacks Investment Research cut CSL from a “hold” rating to a “sell” rating in a research report on Tuesday, April 20th. Macquarie upgraded shares of CSL from a “neutral” rating to an “outperform” rating in a research report on Tuesday. Citigroup upgraded shares of CSL from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 10th. Finally, The Goldman Sachs Group lowered CSL from a “buy” rating to a “neutral” rating in a research note on Thursday, February 18th.
CSL stock traded up $0.81 during midday trading on Tuesday, reaching $105.17. The stock had a trading volume of 50,415 shares, compared to its average volume of 56,835. CSL has a 12 month low of $91.04 and a 12 month high of $117.98. The firm’s 50-day moving average price is $102.34 and its 200 day moving average price is $106.41. The firm has a market capitalization of $95.73 billion, a PE ratio of 45.53 and a beta of 0.59. The company has a quick ratio of 1.37, a current ratio of 3.01 and a debt-to-equity ratio of 0.89.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: What Does Beta Mean In Stock Selection?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.